EFEKTIVITAS BIAYA PENGGUNAAN ANTIBIOTIK PASIEN COVID-19  DI RUMAH SAKIT TADJUDDIN CHALID MAKASSAR

Andi paluseri; Rika Oktaviani; Zulfahmidah Zulfahmidah; Fajriansyah Fajriansyah

doi:10.32382/mf.v17i1.2050

EFEKTIVITAS BIAYA PENGGUNAAN ANTIBIOTIK PASIEN COVID-19 DI RUMAH SAKIT TADJUDDIN CHALID MAKASSAR

Andi paluseri, Rika Oktaviani, Zulfahmidah Zulfahmidah, Fajriansyah Fajriansyah

Abstract

Cost-Effectiveness Analysis Of The Use Of The Antibiotics Levofloxacin And Azithromycin In Patients With Coronavirus Disease 2019

Corona Virus Diseases 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome corona virus 2 (SAR-CoV-2) which causes respiratory infections. This disease requires a large cost in the management process. Therefore, this research aims to analyze the cost-effectiveness in the use of azithromycin and levofloxacin antibiotics in the treatment of COVID-19 at a General hospital in Makassar City. This is an observational cross-sectional research with a prospective data collection method (January-March 2021) and a total sampling technique. Furthermore, data were taken from medical records and part of the financial information system, including patients' characteristics data (medical record number, patient initials, age, gender), clinical data (diagnosis, swab-test results), drug use data (dosage, rules of use, and duration of drug administration), and total medical costs (healthcare perspective: drug, treatment, laboratory, and radiology costs). Moreover, the effectiveness of this study was measured by the number of patients that were declared cured (negative swab-test). The results showed that the ACER value of the levofloxacin and azithromycin antibiotic were Rp. 191,705 and Rp. 157,359 respectively. These results indicate that the azithromycin antibiotic therapy group is more cost-effective compared to the levofloxacin group.

Keywords : Cost Effectiveness, COVID-19, Antibiotics.

Corona Virus Diseases 2019 (COVID-19) merupakan penyakit menular yang disebabkan oleh severe acute respiratory syndrome corona virus 2 (SAR-CoV-2) yang dapat menyebabkan infeksi saluran pernapasan. Penyakit ini membutuhkan biaya besar dalam proses penatalaksanaannya. Penelitian ini bertujuan untuk menganalisis nilai cost-effectiveness penggunaan antibiotik azitromisin dan levofloksasin pada pengobatan COVID-19 pada salah satu Rumah Sakit Umum di Kota Makassar. Desain penelitian ini adalah observasional cross-sectional dengan pengambilan data secara prospektif (Januari-Maret 2021). Teknik pengambilan sampel pada penelitian ini adalah total sampling. Data diambil dari rekam medis pasien dan bagian sistem informasi keuangan pada salah satu Rumah Sakit Umum di Kota Makassar, meliputi data karakteristik pasien (nomor rekam medis, inisial pasien, umur, jenis kelamin), data klinis pasien (diagnosis, hasil swab-test), data penggunaan obat (dosis, aturan pakai, dan lama pemberian obat), data total biaya pengobatan (healthcare perspective: biaya obat, biaya perawatan, biaya laboratorium, biaya radiologi). Efektivitas dalam penelitian ini diukur dari jumlah pasien yang dinyatakan sembuh (hasil pemeriksaan swab-test dinyatakan negatif). Hasil penelitian menunjukan nilai ACER antibiotik levofloksasin sebesar Rp. 191.705 dan nilai ACER antibiotik azitromisin sebesar Rp. 157.359. Hasil ini menunjukan bahwa kelompok terapi antibiotik azitromisin lebih cos-effective dibandingkan dengan kelompok terapi antibiotik levofloksasin.

Kata Kunci : Efektivitas Biaya, COVID-19, Antibiotik

Full Text:

PDF (Bahasa Indonesia)

References

Bacharier, L. B. et al. 2015. Early Administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses a randomized clinical trial, JAMA - Journal of the American Medical Association, 314(19), pp. 2034–2044. doi: 10.1001/jama.2015.13896.

Badan Pengawas Obat dan Makanan Republik Indonesia.2020. Informatorium Obat COVID-19 Di Indonesia. BPOM.Jakarta

Bosseboeuf, E. et al. 2018. Azithromycin Inhibits the Replication of Zika Virus, Journal of Antivirals & Antiretrovirals, 10(1). doi: 10.4172/1948-5964.1000173.

Centers for Disease Controls and Prevention. 2020. Covid-19. CDC USA

Dias, S. et al. 2011. Embedding Evidence Synthesis in Probabilistic Cost-Effectiveness Analysis: Software Choices [Internet]. National Institute for Health and Care Excellence (NICE)

Gautret, P. et al. 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 56(1).

Kementrian Kesehatan Republik Indonesia. 2013. Pedoman Penerapan Kajian Farmakoekonomi, Jenderal Bina Kefarmasian dan Alat Kesehatan.

Noreddin, A. M. and Elkhatib, W. F. 2010. Levofloxacin in the treatment of community-acquired pneumonia, Expert Review of Anti-Infective Therapy, 8(5), pp. 505–514. doi: 10.1586/eri.10.35.

Rascati, K. L. et al. 2004. Education in pharmacoeconomics: An international multidisciplinary view, PharmacoEconomics, 22(3), pp. 139–147. doi: 10.2165/00019053-200422030-00001.

Rees, E. M. et al. 2020. COVID-19 length of hospital stay: a systematic review and data synthesis. medRxiv, (May). doi: 10.1101/2020.04.30.20084780.

Tran, D. H. et al. 2019. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process’, Journal of Antibiotics, 72(10), pp. 759–768. doi: 10.1038/s41429-019-0204-x.

Zhang, Y. et al. 2019. Effects of macrolides on airway microbiome and cytokine of children with bronchiolitis: A systematic review and meta-analysis of randomized controlled trials. Microbiology and Immunology, 63(9), pp. 343–349. doi: 10.1111/1348-0421.12726.

Zimmermann, P. et al. 2018. The immunomodulatory effects of macrolides-A systematic review of the underlying mechanisms. Frontiers in Immunology, 9(MAR). doi: 10.3389/fimmu.2018.00302.

DOI: https://doi.org/10.32382/mf.v17i1.2050